Hemostatic agents

Transfusion

Volumn 44, Issue 12 SUPPL., 2004, Pages

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; APROTININ; DESMOPRESSIN; FIBRIN GLUE; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART SURGERY; HEMOPHILIA; HEMOSTASIS; HUMAN; LUNG EMBOLISM; META ANALYSIS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 10444232098     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0041-1132.2004.04173.x     Document Type: Conference Paper

References (37)

1. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002;76(Suppl 2):139-44.
2. Levy JH. Novel intravenous antithrombins. Am Heart J 2001;141:1043-7.
3. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999;57:233-60.
4. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001;72: S1814-20.
5. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints Lancet. 1999;354:1940-7.
6. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin for repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
7. Alderman EL, Levy JH, Rich J, et al. International multicenter aprotinin graft patency experience (IMAGE). J Thorac Cardiovasc Surg 1998;116:716-30.
8. Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-53.
9. Havel M, Grabenwoger F, Schneider J. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
10. Lemmer JH Jr, Dilling EW, Mortin JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial for three dose regimens. Ann Thorac Surg 1996;62:1659-67.
11. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reop pediatric cardiac surgery. Ann Thorac Surg 1998;66:535-40.
12. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
13. Amar D. Antifibrinolytic therapy and periop blood loss in cancer pts undergoing major orthopedic surgery. Anesthesiology 2003;98:337-42.
14. Capdevila X. Aprotinin decreases blood loss and transfusions in pts undergoing major orthopedic surgery. Anesthesiology 1998;88:50-7.
15. Hayes A. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and DVTs in THR surgery. J Clin Anesth 1996;8:357-60.
16. Janssens M. High-dose aprotinin reduces blood loss in patients undergoing THR surgery. Anesthesiology 1994; 80:23-9.
17. Kasper SMA. retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol 1998;15:669-75.
18. Murkin JM, Haig GM, Beer JK, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 2000;82:675-84.
19. Samama CM, Langeron O, Rosencher N, et al. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg 2002;95: 287-93.
20. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002;9:377-88.
21. Hiippala S, Strid L, Wennerstrand M, et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 1995;74:534-7.
22. Hiippala ST, Strid LJ, Wennerstrand MI, et al. Tranexamic acid radically decreases blood and transfusions associated with total knee arthroplasty. Anesth Analg 1997;84:839-44.
23. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br 1996;78:434-40.
24. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-8.
25. Yasen K, Bellamy MC, Sadek SA, et al. Tranexamic acid reduces blood loss during orthotopic liver transplantation. Clin Transplant 1993;7:453-8.
26. Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987;66:766-73.
27. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999;99:81-9.
28. Cattaneo M, Mannucci PM. Desmopressin and blood loss after cardiac surgery [letter]. Lancet 1993;342:812.
29. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339: 245-53.
30. Karnezis TA, Stulberg SD, Wixson RL, et al. The hemostatic effects of desmopressin on patients who had total joint arthroplasty: a double-blind randomized trial. J Bone Joint Surg Am 1994;76:1545-50.
31. Schott U, Sollen C, Axelsson K, et al. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anesthesiol Scand 1995;39: 592-8.
32. Flordal PA, Ljungstrom KG, Ekman B, et al. Effects of desmopressin on blood loss in hip arthroplasty: controlled study in 50 patients. Acta Orthop Scand 1992;63:381-5.
33. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003;17(Suppl 1):S1-5.
34. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004;79: 103-8.
35. Monroe DM, Hoffman M, Allen GA, et al. The factor VII-platelet interplay: effectiveness of recombinant factorVIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000;26:373-7.
36. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg 2003;76:2094-7.
37. Tanaka KA, Waly AA, Cooper WA., et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factorVIIa (NovoSeven). Anesthesiology 2003;98:1513-5.